A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models-Reference-Cited by-同舟云学术

A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models

Published:2019-03 Issue: Volume:128 Page:162-170
ISSN:0882-4010
Container-title:Microbial Pathogenesis
language:en
Short-container-title:Microbial Pathogenesis

Author:

Bamorovat Mehdi,Sharifi Iraj,Fekri Alireza,Keyhani Alireza,Aflatoonian Mohammad Reza,Heshmatkhah Amireh,Oliaee Razieh Tavakoli,Khosravi Ahmad,Naderi Afsaneh,Parizi Maryam Hakimi,Mostafavi Mahshid,Varma Rajender S.^ORCID

Funder

Vice-Chancellor of Research, Kerman University of Medical Sciences Kerman, Iran

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology

Reference48 articles.

1. Leishmaniasis: current situation and new perspectives;Desjeux;Comp. Immunol. Microbiol. Infect. Dis.,2004

2. A new perspective on cutaneous leishmaniasis implications for global prevalence and burden of disease estimates;Bailey;PLoS Neglected Trop. Dis.,2017

3. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies;Akhoundi;PLoS Neglected Trop. Dis.,2016

4. Epidemiological aspects of cutaneous leishmaniasis in Iran;Khazaei;Arch. Clin. Infect. Dis.,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis;Journal of Epidemiology and Global Health;2024-03-11

2. Cutaneous Leishmaniasis Hampers COVID-19: A Controlled Cross-Sectional Study in High-Burden Endemic Areas of Iran;Journal of Epidemiology and Global Health;2024-01-08

3. Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis;PLOS ONE;2023-09-08

4. Mutual Role of Patients and the Healthcare System in the Control of Cutaneous Leishmaniasis;Transboundary and Emerging Diseases;2023-08-26

5. Models for cytotoxicity screening of antileishmanial drugs: what has been done so far?;International Journal of Antimicrobial Agents;2022-08